July 22, 2010
Nutra Pharma (OTCBB:NPHC) has announced that its drug discovery subsidiary, ReceptoPharm, will be introducing its novel antiviral therapy, PEPTERON, at the International AIDS Conference in Vienna, Austria.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that its drug discovery subsidiary, ReceptoPharm, will be presenting at the International AIDS Conference in Vienna, Austria.
The focus of ReceptoPharm’s presentation will be on its novel antiviral therapy, PEPTERON, which is based on the Company’s leading drug candidate, RPI-MN. RPI-MN has been shown to inhibit the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and HIV. The presentation will be given by Dr. Dorothy Bray, Ph.D., who serves on ReceptoPharm’s Scientific Advisory Board. Previously, Dr. Bray served as the Director of HIV Clinical Development at GlaxoSmithKline (GSK) with global responsibility for their clinical trials program. GSK is currently one of the largest providers of HIV antiretroviral drugs.
“We are pleased to have the opportunity to introduce our antiviral therapy, PEPTERON, at the International AIDS Conference,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As we move forward with our HIV clinical development program, we intend to actively seek out international collaborations and partnerships that will help leverage our ability to bring PEPTERON through the regulatory approval process,” he said.
The International AIDS Conference, which began on July 18 and runs through July 23, 2010, is considered one of the premier conferences for those working in the field of HIV, as well as policy makers, persons living with HIV and other individuals committed to ending the pandemic. The AIDS 2010 program will present new scientific knowledge and offer opportunities for structured dialogue on the major issues facing the global response to HIV.
About Nutra Pharma Corp.
Nutra Pharma Corporation (OTCBB:NPHC) (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.
www.undiscoveredequities.net
www.nutrapharma.com
www.Cobroxin.com
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Sincerely,
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment